Mayne Pharma to present at HC Wainwright conference in NY
Released
Released
Announcement PDF
ASX Announcement
MAYNE PHARMA TO PRESENT AT THE H.C. WAINWRIGHT
25TH ANNUAL GLOBAL INVESTMENT CONFERENCE
7 September 2023, Adelaide, Australia: Mayne Pharma Group Limited (ASX: MYX) today announced
that Shawn Patrick O’Brien, Chief Executive Officer of Mayne Pharma, will present at the H.C.
Wainwright 25th Annual Global Investment Conference in New York City as follows:
Date:
Time:
Webcast:
Monday, September 11, 2023
9:00am US Eastern Time
Click here
To schedule a one-on-one meeting with the Company, please contact meetings@hcwco.com at
H.C. Wainwright.
The live and archived webcast of the presentation will be accessible from the Company’s website
maynepharma.com under Investor Relations. The replay of the webcast will be accessible for 90
days.
For further information contact:
Australia:
Craig Haskins
+61 421 029 843
ir@maynepharma.com
USA:
Lisa M. Wilson
T: 917-543-9932
E: ir@maynepharma.com
Authorised for release to the ASX by the Chair
About Mayne Pharma
Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel
pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma also provides
contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40- year track
record of innovation and success in developing new oral drug delivery systems. These technologies have been
successfully commercialised in numerous products that continue to be marketed around the world. To learn
more about Mayne Pharma, please visit maynepharma.com.
Share your feedback
Discover